Details of the Drug

General Information of Drug (ID: DMWOSKJ)

Drug Name
Zolpidem
Synonyms
zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 307.4
Topological Polar Surface Area (xlogp) 2.5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is rapidly absorbed from the gastrointestinal tract [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 121 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.6 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
72% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The total clearance of drug is 0.24-0.27 mL/min/kg [6]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 hours [3]
Metabolism
The drug is metabolized via various hepatic cytochrome P450 (CYP) isoenzymes [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4669 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.08% [8]
Vd
The volume of distribution (Vd) of drug is 0.54-0.68 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 23 mg/mL [4]
Chemical Identifiers
Formula
C19H21N3O
IUPAC Name
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
Canonical SMILES
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
InChI
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKey
ZAFYATHCZYHLPB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5732
ChEBI ID
CHEBI:10125
CAS Number
82626-48-0
DrugBank ID
DB00425
TTD ID
D0T1WN
INTEDE ID
DR1735
ACDINA ID
D00744

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Modulator [9]
GABA(A) receptor gamma-3 (GABRG3) TTEX6LM GBRG3_HUMAN Modulator (allosteric modulator) [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Zolpidem (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Zolpidem caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [80]
Arn-509 DMT81LZ Moderate Increased metabolism of Zolpidem caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [80]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Zolpidem and Oliceridine. Acute pain [MG31] [81]
Mitotane DMU1GX0 Moderate Increased metabolism of Zolpidem caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [80]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Zolpidem caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [82]
Voriconazole DMAOL2S Moderate Decreased metabolism of Zolpidem caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [83]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Zolpidem caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [84]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of Zolpidem caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [83]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Zolpidem caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [85]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Zolpidem caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [84]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Zolpidem caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [84]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Zolpidem caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [86]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Zolpidem caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [87]
Tucatinib DMBESUA Moderate Decreased metabolism of Zolpidem caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Alpelisib DMEXMYK Moderate Increased metabolism of Zolpidem caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [88]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Zolpidem caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [80]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Zolpidem and Dihydrocodeine. Chronic pain [MG30] [89]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Zolpidem and Olopatadine. Conjunctiva disorder [9A60] [90]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Zolpidem and Propofol. Corneal disease [9A76-9A78] [91]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Zolpidem and Alfentanil. Corneal disease [9A76-9A78] [81]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Zolpidem and Remifentanil. Corneal disease [9A76-9A78] [81]
Mifepristone DMGZQEF Moderate Decreased metabolism of Zolpidem caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [83]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Zolpidem caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [84]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Zolpidem caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [92]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Zolpidem and Ethanol. Cystitis [GC00] [83]
MK-8228 DMOB58Q Moderate Decreased metabolism of Zolpidem caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [93]
Aprepitant DM053KT Moderate Decreased metabolism of Zolpidem caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [94]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Zolpidem caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [84]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Zolpidem and Esketamine. Depression [6A70-6A7Z] [83]
Primidone DM0WX6I Moderate Increased metabolism of Zolpidem caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Zolpidem caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Cenobamate DMGOVHA Moderate Increased metabolism of Zolpidem caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Zolpidem caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Rufinamide DMWE60C Moderate Increased metabolism of Zolpidem caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Phenobarbital DMXZOCG Moderate Increased metabolism of Zolpidem caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Carbamazepine DMZOLBI Moderate Increased metabolism of Zolpidem caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Tazemetostat DMWP1BH Moderate Increased metabolism of Zolpidem caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [80]
Itraconazole DMCR1MV Moderate Decreased metabolism of Zolpidem caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [84]
Miconazole DMPMYE8 Moderate Decreased metabolism of Zolpidem caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [84]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Zolpidem caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [84]
Cimetidine DMH61ZB Moderate Decreased metabolism of Zolpidem caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [84]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Zolpidem and Brimonidine. Glaucoma [9C61] [96]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Zolpidem caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [80]
Boceprevir DMBSHMF Moderate Decreased metabolism of Zolpidem caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [97]
Rifampin DMA8J1G Moderate Increased metabolism of Zolpidem caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [80]
Rifapentine DMCHV4I Moderate Increased metabolism of Zolpidem caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [80]
Delavirdine DM3NF5G Moderate Decreased metabolism of Zolpidem caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Zolpidem caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Efavirenz DMC0GSJ Moderate Increased metabolism of Zolpidem caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Saquinavir DMG814N Moderate Decreased metabolism of Zolpidem caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Etravirine DMGV8QU Moderate Increased metabolism of Zolpidem caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Zolpidem caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Darunavir DMN3GCH Moderate Decreased metabolism of Zolpidem caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Ritonavir DMU764S Minor Decreased metabolism of Zolpidem caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Verapamil DMA7PEW Moderate Decreased metabolism of Zolpidem caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [84]
Conivaptan DM1V329 Moderate Decreased metabolism of Zolpidem caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [101]
Lesinurad DMUR64T Moderate Increased metabolism of Zolpidem caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [80]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Zolpidem caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [84]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Zolpidem caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [80]
Brigatinib DM7W94S Moderate Increased metabolism of Zolpidem caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Ceritinib DMB920Z Moderate Decreased metabolism of Zolpidem caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
PF-06463922 DMKM7EW Moderate Increased metabolism of Zolpidem caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Selpercatinib DMZR15V Moderate Decreased metabolism of Zolpidem caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
Idelalisib DM602WT Moderate Decreased metabolism of Zolpidem caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [103]
IPI-145 DMWA24P Moderate Decreased metabolism of Zolpidem caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
Vemurafenib DM62UG5 Moderate Increased metabolism of Zolpidem caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [80]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Zolpidem caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [80]
Danazol DML8KTN Moderate Decreased metabolism of Zolpidem caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [84]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Zolpidem and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [104]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Zolpidem and Lasmiditan. Migraine [8A80] [105]
Exjade DMHPRWG Moderate Decreased metabolism of Zolpidem caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [106]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Zolpidem and Flibanserin. Mood disorder [6A60-6E23] [107]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Zolpidem and Thalidomide. Multiple myeloma [2A83] [108]
Rifabutin DM1YBHK Moderate Increased metabolism of Zolpidem caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [80]
Nilotinib DM7HXWT Moderate Decreased metabolism of Zolpidem caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [109]
Imatinib DM7RJXL Moderate Decreased metabolism of Zolpidem caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Dasatinib DMJV2EK Moderate Decreased metabolism of Zolpidem caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [110]
Modafinil DMYILBE Moderate Increased metabolism of Zolpidem caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [80]
Entrectinib DMMPTLH Moderate Decreased metabolism of Zolpidem caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [84]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Zolpidem and Levomethadyl Acetate. Opioid use disorder [6C43] [89]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Zolpidem and Apraclonidine. Optic nerve disorder [9C40] [96]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Zolpidem caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [84]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Zolpidem and Pentazocine. Pain [MG30-MG3Z] [81]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Zolpidem and Dextropropoxyphene. Pain [MG30-MG3Z] [111]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Zolpidem and Butorphanol. Pain [MG30-MG3Z] [81]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Zolpidem and Oxymorphone. Pain [MG30-MG3Z] [81]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Zolpidem and Levorphanol. Pain [MG30-MG3Z] [81]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Zolpidem and Dezocine. Pain [MG30-MG3Z] [81]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Zolpidem and Nalbuphine. Pain [MG30-MG3Z] [81]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Zolpidem and Buprenorphine. Pain [MG30-MG3Z] [112]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Zolpidem and Hydrocodone. Pain [MG30-MG3Z] [81]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Zolpidem and Meperidine. Pain [MG30-MG3Z] [81]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Zolpidem and Oxycodone. Pain [MG30-MG3Z] [81]
Abametapir DM2RX0I Moderate Decreased metabolism of Zolpidem caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [113]
Lefamulin DME6G97 Moderate Decreased metabolism of Zolpidem caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [114]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Zolpidem caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [84]
Enzalutamide DMGL19D Moderate Increased metabolism of Zolpidem caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [80]
Bosentan DMIOGBU Moderate Increased metabolism of Zolpidem caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [80]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Zolpidem and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [115]
Dexamethasone DMMWZET Moderate Increased metabolism of Zolpidem caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [80]
Nafcillin DMN9RPO Moderate Increased metabolism of Zolpidem caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [80]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Zolpidem and Fentanyl. Sensation disturbance [MB40] [81]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Zolpidem and Sufentanil. Sensation disturbance [MB40] [81]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Zolpidem caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [84]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Zolpidem caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [80]
Larotrectinib DM26CQR Moderate Decreased metabolism of Zolpidem caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Armodafinil DMGB035 Moderate Increased metabolism of Zolpidem caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [80]
LEE011 DMMX75K Moderate Decreased metabolism of Zolpidem caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Zolpidem caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [116]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Zolpidem and Tizanidine. Tonus and reflex abnormality [MB47] [117]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Zolpidem and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [115]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Zolpidem and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [115]
⏷ Show the Full List of 112 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Calcium hydrogenphosphate E00294 24441 Diluent
Carbonic acid disodium salt E00199 10340 Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Magnesium tartrate E00514 13014144 Other agent
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium bitartrate E00551 23666342 Antioxidant; Buffering agent; Complexing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 43 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zolpidem 1.75 mg tablet 1.75 mg Sublingual Tablet Oral
Zolpidem 3.5 mg tablet 3.5 mg Sublingual Tablet Oral
Zolpidem 5 mg tablet 5 mg Oral Tablet Oral
Zolpidem 10 mg tablet 10 mg Sublingual Tablet Oral
Zolpidem 5 mg tablet 5 mg Sublingual Tablet Oral
Zolpidem 10 mg tablet 10 mg Oral Tablet Oral
Zolpidem 12.5 mg tablet 12.5 mg Extended Release Oral Tablet Oral
Zolpidem 6.25 mg tablet 6.25 mg Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4348).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 LaCagnin LB, Lutsie P, Colby HD: Conversion of spironolactone to 7 alpha-thiomethylspironolactone by hepatic and renal microsomes. Biochem Pharmacol. 1987 Oct 15;36(20):3439-44.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
11 Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
12 Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
13 The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
14 Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
15 Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00849.
16 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
17 Principles of Clinical Pharmacology (Third Edition). 2012, Pages 417-436
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
28 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
29 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
30 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
31 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
32 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
33 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
34 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
35 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
36 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
45 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
46 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
47 Drug Interactions Flockhart Table
48 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
49 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
50 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
51 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
52 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
53 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
54 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
55 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
56 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
57 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
58 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
59 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
60 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
61 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
62 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
63 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
64 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
65 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
66 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
67 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
68 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
69 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
70 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
71 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
72 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
73 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
74 Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
75 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
76 Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96.
77 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
78 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
79 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
80 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
81 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
82 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
83 Cerner Multum, Inc. "Australian Product Information.".
84 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
85 Greenblatt DJ, vonMoltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, RothSchechter B, Shader RI "Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole." Clin Pharmacol Ther 64 (1998): 661-71. [PMID: 9871431]
86 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
87 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
88 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
89 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
90 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
91 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
92 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
93 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
94 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
95 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
96 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
97 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
98 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
99 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
100 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
101 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
102 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
103 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
104 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
105 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
106 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
108 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
109 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
110 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
111 Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
112 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
113 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
114 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
115 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
116 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
117 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.